Trade Report: Today, Virginia Retirement Systems ET AL Buys New Stake in Horizon Pharma Inc. (HZNP)

Today, Virginia Retirement Systems ET AL Buys New Stake in Horizon Pharma Inc. (HZNP)

Virginia Retirement Systems ET AL bought a new stake in Horizon Pharma Inc. (NASDAQ:HZNP) during the third quarter, Holdings Channel reports. The firm bought 18,600 shares of the biopharmaceutical company’s stock, valued at approximately $337,000.

Other hedge funds also recently added to or reduced their stakes in the company. Capital Fund Management S.A. raised its stake in Horizon Pharma by 142.9% in the third quarter. Capital Fund Management S.A. now owns 131,241 shares of the biopharmaceutical company’s stock valued at $2,379,000 after buying an additional 77,214 shares during the period. Rothschild Asset Management Inc. raised its stake in Horizon Pharma by 76.5% in the third quarter. Rothschild Asset Management Inc. now owns 913,130 shares of the biopharmaceutical company’s stock valued at $16,555,000 after buying an additional 395,830 shares during the period. Strs Ohio raised its stake in Horizon Pharma by 3.8% in the third quarter. Strs Ohio now owns 21,800 shares of the biopharmaceutical company’s stock valued at $395,000 after buying an additional 800 shares during the period. HL Financial Services LLC acquired a new stake in Horizon Pharma during the third quarter valued at $196,000. Finally, Boston Advisors LLC raised its stake in Horizon Pharma by 7.3% in the third quarter. Boston Advisors LLC now owns 24,125 shares of the biopharmaceutical company’s stock valued at $437,000 after buying an additional 1,640 shares during the period. 87.91% of the stock is currently owned by institutional investors.

Shares of Horizon Pharma Inc. (NASDAQ:HZNP) traded down 0.97% during midday trading on Friday, reaching $21.49. The company’s stock had a trading volume of 630,634 shares. Horizon Pharma Inc. has a 12-month low of $13.05 and a 12-month high of $23.44. The company’s market capitalization is $3.47 billion. The company’s 50-day moving average price is $18.68 and its 200 day moving average price is $18.49.

Horizon Pharma (NASDAQ:HZNP) last announced its earnings results on Monday, November 7th. The biopharmaceutical company reported $0.70 earnings per share for the quarter, topping analysts’ consensus estimates of $0.63 by $0.07. The business had revenue of $273.70 million for the quarter, compared to analyst estimates of $270.04 million. Horizon Pharma had a positive return on equity of 22.73% and a negative net margin of 1.34%. The company’s quarterly revenue was up 20.8% compared to the same quarter last year. During the same period in the prior year, the company earned $0.70 EPS. On average, equities research analysts forecast that Horizon Pharma Inc. will post $2.02 earnings per share for the current year.

Several research firms recently weighed in on HZNP. Zacks Investment Research raised Horizon Pharma from a “hold” rating to a “buy” rating and set a $25.00 price objective on the stock in a research note on Wednesday, August 10th. Brean Capital reaffirmed a “buy” rating and issued a $30.00 price objective on shares of Horizon Pharma in a research note on Tuesday, August 9th. Guggenheim reaffirmed a “buy” rating and issued a $30.00 price objective on shares of Horizon Pharma in a research note on Tuesday, August 23rd. Mizuho reaffirmed a “buy” rating and issued a $30.00 price objective (up from $24.00) on shares of Horizon Pharma in a research note on Wednesday, August 10th. Finally, BMO Capital Markets reaffirmed an “outperform” rating and issued a $30.00 price objective (up from $29.00) on shares of Horizon Pharma in a research note on Wednesday, August 10th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, nine have issued a buy rating and one has given a strong buy rating to the stock. Horizon Pharma has an average rating of “Buy” and an average target price of $29.69.

Horizon Pharma Company Profile

Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products. It markets approximately nine medicines through its orphan, primary care and rheumatology business units.

Related posts

Leave a Comment